Abbott Laboratories (ABT) Cash from Investing Activities (2009 - 2026)

Abbott Laboratories has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$20.3 billion for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$20.3 billion, down 4224.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.3 billion (down 834.79% YoY), and the FY2025 annual result was -$2.4 billion, down 3.59% from the prior year.
• Cash from Investing Activities came in at -$20.3 billion for Q1 2026 at Abbott Laboratories, down from -$913.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$264.0 million in Q2 2022 to a low of -$20.3 billion in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$582.0 million (2025), against an average of -$1.8 billion.
• Across the five-year window, Cash from Investing Activities jumped 62.65% in 2024 and plunged 4224.26% in 2026, its largest moves.
• Abbott Laboratories' Cash from Investing Activities stood at -$632.0 million in 2022, then sank by 30.38% to -$824.0 million in 2023, then dropped by 5.1% to -$866.0 million in 2024, then declined by 5.43% to -$913.0 million in 2025, then plunged by 2126.07% to -$20.3 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$20.3 billion (Q1 2026), -$913.0 million (Q4 2025), and -$457.0 million (Q3 2025), per Business Quant data.